Abpro Stock

Abpro is a biotechnology company focused on therapeutics, diagnostics, and research.

Sign up today and learn more about Abpro Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Abpro Stock

Abpro is a biotechnology company dedicated to accelerating biological research by providing superior tools to researchers worldwide. As a pioneer of industrial biochemistry and an emerging leader in the reagents field, they have developed a proprietary technology platform that allows for faster, more efficient production of recombinant proteins and antibodies. As a result, Abpro delivers superior quality products at industry-leading speeds. Abpro leveraging these platforms, both independently and through collaborations with global pharmaceutical companies and research institutions to develop therapeutic antibodies for use in immuno-oncology, ophthalmology, and other disease areas. The DiversImmune platform enables the generation of novel antibodies and next-generation antibody therapies.

Funding History

March 2016$12.4M
April 2017$10.0M
January 2020$18.0M
April 2022$2.0M



Eugene Cha


John Xu

Chairman & CEO

Ian Chan


Robert J. Markelewicz


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: